The stakes are high because AGASACA behaves in a paradoxical way. Although the primary tumor at the anal sac can be small at diagnosis, metastatic lymph nodes in the sublumbar region can grow large enough to partially obstruct the rectum, creating life-threatening consequences from disease that started in a gland the size of a pea. The disease also tends to progress relatively slowly compared with many other malignancies, which means that long-term locoregional control, rather than a rapid strike against distant spread, is the single most important goal for a successful outcome. Late in the disease course, metastases can also appear in distant organs such as the lungs, but it is the pelvic battlefield where most treatment decisions are won or lost.

Surgery has long been considered the first line of defense. Yet the review makes clear that the surgical landscape is more complicated than many clients realize. Local recurrence of the primary tumor after resection has been reported in anywhere from 4 to 44 percent of cases, with a median time to recurrence ranging from 140 to 374 days. When surgeons attempt to remove metastatic iliosacral lymph nodes, recurrence within the lymphocentrum has been documented in between roughly 12 and 59 percent of cases, sometimes within just six months of the operation. Perioperative complications occur in 12 to 39 percent of patients, and the most feared complication, hemorrhage during lymph node extirpation, affects up to 18 percent of dogs, with mortality reaching 2.2 percent. Critically, the risk of complications climbs sharply when lymph nodes exceed 4.5 centimeters in size, a threshold that should prompt especially careful conversations between veterinarians and owners.

Patterns of treatment failure tell a coherent story across studies. In one investigation of 34 dogs with early-stage disease treated with surgery alone, 21 percent developed local recurrence of the primary tumor at a median of 354 days, and 26 percent developed locoregional metastases at a median of 589 days. A larger study of 161 dogs stratified patients by surgical margins, using the familiar R0, R1, and R2 classification system, and found that only the presence of lymphovascular invasion and an R1 resection, in which tumor cells extend to the cut edge of the specimen, were statistically associated with recurrence. In dogs with massive primary tumors greater than 5 centimeters, none of the stage 2 patients developed lymph node metastasis, while more than half of those presenting with stage 3 disease progressed further. The unifying message is that disease stage at initial treatment mediates the risk of relapse, which implies that adjuvant therapies should be deployed on a risk-based basis rather than universally.

This is where radiation therapy enters the picture, and where the review offers its most nuanced analysis. Conventionally fractionated definitive radiotherapy, or CFDRT, aims to deliver the highest possible dose to residual tumor cells while respecting the tolerance of surrounding normal tissues, typically in 16 to 20 fractions of 2.5 to 3 Gy for total doses of 48 to 50 Gy. The problem is that its clinical role in microscopic AGASACA after surgery remains poorly defined. In a study of 113 variably treated dogs, adjuvant radiation did not produce a significant improvement in survival time, though the small number of irradiated patients and the slow natural history of the tumor may have masked a real effect. Meanwhile, dogs undergoing CFDRT develop moderate to severe acute side effects in organs at risk including the rectum, colon, urinary bladder, skin, and spinal cord, with recovery from acute toxicity taking 23 to 36 days after onset. The therapeutic index, the ratio of benefit to harm, may simply not be favorable enough for this approach in every patient.

The most striking finding in the review concerns hypofractionated radiotherapy for advanced disease. In a study comparing hypofractionated radiation against surgical extirpation of iliosacral lymph nodes in dogs with stage 3b AGASACA, radiation produced significantly longer outcomes: a median progression-free interval of 347 days versus 159 days for surgery, and a median survival time of 447 days versus 182 days. The authors offer a compelling technical explanation rooted in the geometry of radiation planning. When radiation oncologists contour a CT scan, they delineate all visible gross disease as the gross tumor volume, then add margins for subclinical microscopic extension to create the clinical target volume, and finally add further margin for setup uncertainty to create the planning target volume. This means radiation can treat the entire iliosacral lymphocentrum, including microscopic disease threading through the lymphatic network, in a way that no surgeon’s hands can match. Surgery removes individual enlarged nodes; radiation can sterilize the whole nodal basin.

Even the terminology of palliative care may need revision for this disease. Protocols delivering 20 Gy in five daily 4 Gy fractions, often labeled palliative because of their low total dose, have produced median progression-free survival of 289 to 347 days and median survival times of 329 to 447 days in AGASACA patients. For comparison, across a broad range of other tumor types treated with the same 4 Gy by 5 protocol, median progression-free survival was only 4.4 months. AGASACA appears roughly twice as responsive as expected, suggesting the tumor may harbor a low alpha-beta ratio, the radiobiological parameter that determines sensitivity to large fraction sizes, consistent with its slowly proliferating nature. The authors argue that defining treatment intent purely by fraction size and number may be inappropriate when a so-called palliative regimen delivers a year of disease control with mostly mild, grade 1 to 2 gastrointestinal side effects.

Not every advanced technique earns endorsement. Stereotactic body radiotherapy, which delivers ablative doses of 6 to 10 Gy per fraction over 3 to 5 fractions, showed promising survival numbers in small studies, with one report of a 991-day median survival in five dogs. But the largest SBRT study to date, involving 25 dogs treated for metastatic sublumbar lymph nodes, revealed a sobering safety signal: 48 percent of dogs developed late-onset changes in gait and hind limb lameness, including ataxia, paraparesis, weakness, and pain. The authors recommend reserving SBRT for macroscopic disease rather than microscopic tumor beds, and focusing treatment on the nodal region while addressing the primary site surgically. Chemoradiotherapy fares even worse in the evidence hierarchy. The largest dataset, 15 dogs treated with concurrent mitoxantrone, produced a 93 percent rate of severe moist desquamation and a 53 percent rate of clinically relevant late effects, including two dogs euthanized for chronic colorectal toxicity. The review concludes there is insufficient evidence to recommend routine chemoradiotherapy in this disease.

One further clinical pearl concerns hypercalcemia of malignancy, a paraneoplastic syndrome affecting 27 to 34 percent of AGASACA patients that can become an emergency when total calcium exceeds 16 mg/dL. Hypofractionated radiation resolved hypercalcemia in about 31 percent of cases alone, rising to 77 percent when combined with steroids or bisphosphonates, offering a non-surgical route to controlling this dangerous metabolic derangement. Looking forward, the authors call for prospective trials comparing fractionation schemes, systematic imaging-based assessment of response rates, and rigorous studies of patterns of failure. Modern technology, including intensity-modulated radiation therapy and cone beam CT image guidance, should theoretically reduce both acute and late toxicities compared with the older two-dimensional planning used in much of the published literature, though no study has yet confirmed this. For now, the review’s practical bottom line is clear: surgery remains the cornerstone for the primary tumor, radiation deserves serious consideration, and may even be preferred, for advanced nodal disease, and the humble five-fraction protocol may deserve a better name than palliative.

Subject of Research: The role of radiotherapy in treating canine apocrine gland anal sac adenocarcinoma

Article Title: Role of radiotherapy in canine apocrine gland anal sac adenocarcinoma: a review

Article References: Murakami, K., & Rancilio, N. (2025). Role of radiotherapy in canine apocrine gland anal sac adenocarcinoma: a review. Veterinary Oncology, 2(1), Article 12. https://doi.org/10.1186/s44356-025-00028-1

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00028-1

Keywords: canine cancer, AGASACA, radiotherapy, veterinary oncology, hypofractionated radiation, SBRT, iliosacral lymph nodes, hypercalcemia, chemoradiotherapy, surgical oncology, dogs, radiation side effects

Thymomas are tumors arising from the epithelial cells of the thymus, the organ behind the breastbone where immune cells called T lymphocytes mature. In goats, the thymus has paired cranial and cervical lobes plus a single thoracic lobe, and tumors can develop in the cranial mediastinum, the space between the lungs, or in the ventral neck region. Post-mortem surveys suggest thymomas make up roughly ten percent of all tumors in goats, and dairy breeds such as Nigerian Dwarf and Saanen may carry an even higher prevalence, with one classic study reporting rates as high as twenty-five percent. Despite how common they appear to be at necropsy, almost nothing has been published about actually treating them.

The goat arrived at the University of Florida Large Animal Hospital after several days of lethargy, fever, and reduced appetite. On examination she was febrile at 106.2 degrees Fahrenheit, with rapid heart and respiratory rates, hyperemic mucous membranes, poor rumen contractions, and a heart murmur. Bloodwork revealed elevated fibrinogen and creatine kinase, low protein and calcium, and abnormalities on venous blood gas. A point-of-care thoracic ultrasound uncovered the likely culprit: a mass in the cranial mediastinum, alongside B-line artifacts and small areas of consolidation in the front of the chest that pointed to pneumonia.

A computed tomography scan performed under general anesthesia characterized the mass in detail. It measured 8.6 by 6.5 by 6 centimeters, appeared heterogeneous in soft tissue and fluid attenuation, and enhanced strongly with contrast. The tumor was displacing the cranial vena cava caudodorsally, pushing the heart backward, and compressing the cranial lung lobes, but there was no vascular invasion. Ultrasound-guided fine-needle aspiration yielded lymphoid tissue with poorly preserved epithelial cell aggregates and occasional mast cells, findings most consistent with a neoplasm of thymic origin, suspected to be a thymoma. The team also identified patterns consistent with aspiration or chronic bronchopneumonia and treated the goat empirically with florfenicol.

Treatment options were weighed carefully with the owner. Surgical excision was declined because of the substantial risk of intraoperative hemorrhage, a complication that has proven fatal in the only two goats previously reported to undergo thoracic surgery for mediastinal thymoma. Radiation therapy was offered instead, with candid discussion of acute risks including pneumonitis, esophagitis, tracheitis, and myocarditis, and late risks such as cardiomyopathy, arrhythmia, and lung fibrosis. The owner elected a palliative-intent protocol of four weekly fractions of 8 Gy, totaling 32 Gy, a schedule chosen to reduce costs and minimize the number of hospital visits and anesthetic episodes.

The technical execution of the plan illustrates how far veterinary radiation oncology has come. The goat was positioned in sternal recumbency in a vacuum-sealed cushion for a planning CT scan. The contrast-enhancing mass was contoured as the gross tumor volume, expanded uniformly by 2 millimeters to create the planning target volume. Because thymomas typically move little with respiration, no internal target volume was used, and the small margin prioritized sparing nearby organs at risk: the lungs, heart, esophagus, trachea, and spinal cord. An inverse-planned intensity-modulated plan with eight coplanar isocentric beams was generated on the Eclipse planning system, normalized so that 95 percent of the target received the full prescription dose, with only 5.6 percent of lung volume receiving 20 Gy or more.

Quality assurance was rigorous. The plan was verified with a two-dimensional diode array, requiring at least 95 percent of measured points to agree with the calculated fluence at a 3 percent and 3 millimeter criterion. Treatment was delivered with 6 MV photons from a Varian Edge linear accelerator equipped with a 120-leaf multileaf collimator, and cone-beam CT scans taken before each session confirmed accurate positioning. Each fraction required general anesthesia, induced with propofol after butorphanol and midazolam premedication and maintained on isoflurane, with no complications. By the fourth fraction, the cone-beam CT already showed the tumor shrinking by roughly 5 millimeters in every dimension, and the goat’s appetite had returned to normal while her heart murmur had quieted.

The response endured. A recheck CT scan four months after treatment, performed during an unrelated emergency visit for fever and lethargy, showed the mass had shrunk to 6 by 4.6 by 5.2 centimeters, a 30 percent reduction that meets the formal definition of a partial response under Veterinary Cooperative Oncology Group RECIST criteria. The pulmonary changes seen before treatment had nearly resolved. A scan at ten months confirmed a persistent partial response, though it also revealed mild progression of lower airway inflammation and bronchopneumonia that the authors could not rule out as a low-grade late radiation effect or unrelated chronic bronchitis. Twenty months out, the owner reported only occasional mild coughing, and the goat was still alive at the time of manuscript submission, roughly 1,230 days after treatment began.

The result carries weight because the comparative literature is so thin. Only one previous goat with a cranial mediastinal thymoma had been treated with radiation, receiving 32 Gy in 4 Gy fractions every other day, with tumor regression noted by the sixth fraction and survival of at least 1.5 years. In dogs and cats, surgery remains the treatment of choice for thymoma, though perioperative mortality approaches 20 percent, and radiation produces overall response rates of 33 to 75 percent with median survival times of 5 to 8 months in dogs and 24 months in cats. Because metastasis is rarely seen in caprine thymoma, local control is the central therapeutic goal in goats as well, making radiation an attractive alternative when thoracic surgery is too risky or unavailable.

The authors acknowledge limitations, most notably that the diagnosis rested on cytology rather than the histopathology required for definitive confirmation of thymoma. They also note that the link between the goat’s pneumonia and the tumor is uncertain; in dogs, thymoma-associated megaesophagus drives aspiration pneumonia, but myasthenia gravis appears far less common in goats, and no megaesophagus was seen on CT. Still, the message is clear. As goats increasingly live as companion animals rather than production livestock, cancer care becomes a relevant expectation for their owners, and this case demonstrates that modern, image-guided, hypofractionated radiation therapy is technically feasible in goats, was well tolerated, and can produce objective, durable tumor shrinkage. Larger cohorts will be needed before firm recommendations can be made, but for pet goats facing inoperable mediastinal thymoma, radiation therapy now stands as a legitimate option to discuss.

Subject of Research: Palliative hypofractionated image-guided intensity-modulated radiation therapy for a cranial mediastinal thymoma in a Nigerian Dwarf goat

Article Title: Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report

Article References: Argenti, T., Jodzio, D., Hancock, K., Darby, S., Luethy, D., Gilor, S., Gutti, J., & Takada, M. (2026). Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report. Veterinary Oncology, 3(1), Article 4. https://doi.org/10.1186/s44356-026-00055-6

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00055-6

Keywords: thymoma, goat, radiation therapy, IMRT, veterinary oncology, Nigerian Dwarf goat, mediastinal mass, hypofractionated radiation, computed tomography, palliative care, caprine neoplasia, partial response